WallStreetZenWallStreetZen

NASDAQ: RPRX
Royalty Pharma PLC Stock

$26.92-0.28 (-1.03%)
Updated Jun 14, 2024
RPRX Price
$26.92
Fair Value Price
$78.54
Market Cap
$16.08B
52 Week Low
$25.92
52 Week High
$31.93
P/E
15.04x
P/B
1.63x
P/S
6.09x
PEG
0.3x
Dividend Yield
1.49%
Revenue
$2.24B
Earnings
$798.86M
Gross Margin
100%
Operating Margin
43.93%
Profit Margin
35.7%
Debt to Equity
0.64
Operating Cash Flow
$3B
Beta
0.63
Next Earnings
Aug 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RPRX Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RPRX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RPRX ($26.92) is undervalued by 65.72% relative to our estimate of its Fair Value price of $78.54 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RPRX ($26.92) is significantly undervalued by 65.72% relative to our estimate of its Fair Value price of $78.54 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RPRX ($26.92) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more RPRX due diligence checks available for Premium users.

Be the first to know about important RPRX news, forecast changes, insider trades & much more!

RPRX News

Valuation

RPRX fair value

Fair Value of RPRX stock based on Discounted Cash Flow (DCF)
Price
$26.92
Fair Value
$78.54
Undervalued by
65.72%
RPRX ($26.92) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RPRX ($26.92) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RPRX ($26.92) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RPRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
15.04x
Industry
-10.23x
Market
30.51x
RPRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RPRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

RPRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.63x
Industry
6.25x
RPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RPRX price to earnings growth (PEG)

For valuing profitable companies with growth potential
RPRX is good value based... subscribe to Premium to read more.
PEG Value Valuation

RPRX's financial health

Profit margin

Revenue
$568.0M
Net Income
$4.8M
Profit Margin
0.8%
RPRX's Earnings (EBIT) of $983.33M... subscribe to Premium to read more.
Interest Coverage Financials
RPRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$16.1B
Liabilities
$6.3B
Debt to equity
0.64
RPRX's short-term assets ($1.56B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RPRX's long-term liabilities ($6.14B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$664.6M
Investing
-$86.7M
Financing
-$212.0M
RPRX's operating cash flow ($2.62B)... subscribe to Premium to read more.
Debt Coverage Financials

RPRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RPRX$16.08B-1.03%15.04x1.63x
BMRN$15.86B-0.87%76.61x3.13x
BGNE$17.02B-2.28%-280.31x5.06x
GMAB$17.32B-0.83%21.81x3.70x
INCY$13.95B-0.93%18.65x2.59x

Royalty Pharma Stock FAQ

What is Royalty Pharma's quote symbol?

(NASDAQ: RPRX) Royalty Pharma trades on the NASDAQ under the ticker symbol RPRX. Royalty Pharma stock quotes can also be displayed as NASDAQ: RPRX.

If you're new to stock investing, here's how to buy Royalty Pharma stock.

What is the 52 week high and low for Royalty Pharma (NASDAQ: RPRX)?

(NASDAQ: RPRX) Royalty Pharma's 52-week high was $31.93, and its 52-week low was $25.92. It is currently -15.69% from its 52-week high and 3.86% from its 52-week low.

How much is Royalty Pharma stock worth today?

(NASDAQ: RPRX) Royalty Pharma currently has 597,437,271 outstanding shares. With Royalty Pharma stock trading at $26.92 per share, the total value of Royalty Pharma stock (market capitalization) is $16.08B.

Royalty Pharma stock was originally listed at a price of $44.50 in Jun 16, 2020. If you had invested in Royalty Pharma stock at $44.50, your return over the last 3 years would have been -39.51%, for an annualized return of -15.43% (not including any dividends or dividend reinvestments).

How much is Royalty Pharma's stock price per share?

(NASDAQ: RPRX) Royalty Pharma stock price per share is $26.92 today (as of Jun 14, 2024).

What is Royalty Pharma's Market Cap?

(NASDAQ: RPRX) Royalty Pharma's market cap is $16.08B, as of Jun 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Royalty Pharma's market cap is calculated by multiplying RPRX's current stock price of $26.92 by RPRX's total outstanding shares of 597,437,271.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.